Literature DB >> 2814068

Group sequential procedures: calendar versus information time.

D L Demets1.   

Abstract

This paper describes the relationship between information time and calendar time in the use of group sequential procedures to monitor interim analyses of clinical trials. Information time is the proportion of maximum subjects or events already observed. Interim analyses often occur at specified calendar times while the definition of classic group sequential procedures occurs in terms of information time. We extend the general group sequential approach of Lan and DeMets to include this situation as well.

Entities:  

Mesh:

Year:  1989        PMID: 2814068     DOI: 10.1002/sim.4780081003

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  17 in total

1.  Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.

Authors:  Joann L Ater; Tianni Zhou; Emiko Holmes; Claire M Mazewski; Timothy N Booth; David R Freyer; Ken H Lazarus; Roger J Packer; Michael Prados; Richard Sposto; Gilbert Vezina; Jeffrey H Wisoff; Ian F Pollack
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

3.  Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)

Authors:  M Lorenz; H H Müller; H Schramm; H J Gassel; H G Rau; K Ridwelski; J Hauss; R Stieger; K W Jauch; W O Bechstein; A Encke
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

4.  An insight into the properties of a two-stage design in bioequivalence studies.

Authors:  Vangelis Karalis; Panos Macheras
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

5.  Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.

Authors:  Furqan Shaikh; John W Cullen; Thomas A Olson; Farzana Pashankar; Marcio H Malogolowkin; James F Amatruda; Doojduen Villaluna; Mark Krailo; Deborah F Billmire; Frederick J Rescorla; Rachel A Egler; Bryan J Dicken; Jonathan H Ross; Marc Schlatter; Carlos Rodriguez-Galindo; A Lindsay Frazier
Journal:  J Clin Oncol       Date:  2017-02-27       Impact factor: 44.544

6.  Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group.

Authors:  Deborah F Billmire; John W Cullen; Frederick J Rescorla; Mary Davis; Marc G Schlatter; Thomas A Olson; Marcio H Malogolowkin; Farzana Pashankar; Doojduen Villaluna; Mark Krailo; Rachel A Egler; Carlos Rodriguez-Galindo; A Lindsay Frazier
Journal:  J Clin Oncol       Date:  2014-01-06       Impact factor: 44.544

7.  SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

Authors:  George T Budd; William E Barlow; Halle C F Moore; Timothy J Hobday; James A Stewart; Claudine Isaacs; Muhammad Salim; Jonathan K Cho; Kristine J Rinn; Kathy S Albain; Helen K Chew; Gary V Burton; Timothy D Moore; Gordan Srkalovic; Bradley A McGregor; Lawrence E Flaherty; Robert B Livingston; Danika L Lew; Julie R Gralow; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2014-11-24       Impact factor: 44.544

8.  Cancer screening trials: nuts and bolts.

Authors:  Philip C Prorok; Pamela M Marcus
Journal:  Semin Oncol       Date:  2010-06       Impact factor: 4.929

9.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

10.  Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators.

Authors:  A J Cowley; A M Skene
Journal:  Br Heart J       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.